A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis

被引：19

作者：

vanOosten, BW

Rep, MHG

vanLier, RAW

Scholten, PET

vonBlomberg, BME

Pflughaupt, KW

Hartung, HP

Ader, HJ

Polman, CH

机构：

[1] FREE UNIV AMSTERDAM HOSP,DEPT NEUROL,1007 MB AMSTERDAM,NETHERLANDS

[2] NETHERLANDS RED CROSS,TRANSFUS SERV,DEPT CLIN VIROIMMUNOL,1006 AD AMSTERDAM,NETHERLANDS

[3] FREE UNIV AMSTERDAM HOSP,DEPT PATHOL,1007 MB AMSTERDAM,NETHERLANDS

[4] UNIV WURZBURG,DEPT NEUROL,D-97080 WURZBURG,GERMANY

[5] FREE UNIV AMSTERDAM,FAC MED,DEPT EPIDEMIOL & BIOSTAT,1081 BT AMSTERDAM,NETHERLANDS

来源：

JOURNAL OF NEUROIMMUNOLOGY | 1996年 / 66卷 / 1-2期

关键词：

multiple sclerosis; pentoxifylline; treatment; tumor necrosis factor-alpha;

D O I：

10.1016/0165-5728(96)00019-7

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Multiple sclerosis is probably mainly mediated by T-helper 1 (T(H)1)-lymphocytes. T(H)1-function can be down-regulated in vitro and in animal experiments by pentoxifylline. Therefore, we included 20 multiple sclerosis patients in an open label pilot trial of pentoxifylline. Outcome parameter was the effect of treatment on levels of various cytokines and adhesion molecules in cerebrospinal fluid and serum, on production of T(H)1- and T(H)2-cytokines using cell stimulation assays, as well as on measures of T-cell activation and proliferation. Kurtzke's EDSS was a secondary efficacy parameter. A convincing and consistent effect of pentoxifylline could not be demonstrated.

引用

页码：49 / 55

页数：7

共 55 条

[1] CONTROL OF ESTABLISHED EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS BY INHIBITION OF TUMOR-NECROSIS-FACTOR (TNF) ACTIVITY WITHIN THE CENTRAL-NERVOUS-SYSTEM USING MONOCLONAL-ANTIBODIES AND TNF RECEPTOR IMMUNOGLOBULIN FUSION PROTEINS [J].